Drug maker MedImmune and the University of Maryland, Baltimore have entered into a $6 million partnership to conduct bioscience research.
Under the five-year agreement, Gaithersburg-based MedImmune and the university will provide funding and scientists to work on joint research they hope will result in quicker development of drugs.
The research will focus on cardiovascular and metabolic disease; oncology; respiratory, inflammation and autoimmunity; and infectious disease – areas MedImmune is already strong in.
MedImmune will contribute $5 million and the university $1 million.
The University of Maryland, College Park and University of Maryland, Baltimore County are also a part of the collaboration.
The Department of Business & Economic Development will also contribute funding based on what is available during the five years.
We've upgraded our reader commenting system. Learn more
about the new features.
The Baltimore Sun encourages civil dialogue related to our stories; you must register and log-in to our site in order to participate. We reserve the right to remove any user and to delete comments that violate our Terms of Service
. By commenting, you agree to these terms. Please flag inappropriate comments.